[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vishwajit Nimgaonkar, MD PhD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100430646",false,"NCT04887792","Acetazolamide for Treatment Resistant Schizophrenia","A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia","APTS","Inclusion Criteria:\n\n* Written informed consent.\n* Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).\n* PANSS total score \\> 60 and Score \\> 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions.\n* Stable dose of antipsychotic drug (APD) for \\> 1 month, continued throughout the study.\n* Not participating in another randomized controlled clinical trial (RCT).\n\nExclusion Criteria:\n\n* Substance abuse in the past month\u002Fdependence past 6 months with the exception of methadone prescribed for opiate withdrawal.\n* History or current medical\u002Fneurological illnesses that may lead to unstable course, e.g., epilepsy.\n* Pregnancy.\n* Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease\u002Fadrenal failure; chronic closed angle-closure glaucoma.\n* Current or prior treatment with ACZ or history of hypersensitivity to ACZ.\n* Intellectual disability as defined in DSM 5.","ALL","18 Years","55 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.",[28,29],"Schizophrenia","Schizo Affective Disorder",[28,29,31],"acetazolamide","RECRUITING","2026-04-06",{"date":35,"type":36},"2026-04-07","ACTUAL",{"date":38,"type":36},"2022-02-01",{"date":40,"type":21},"2026-12-30",{"name":42,"class":43},"Vishwajit Nimgaonkar, MD PhD","OTHER",{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100346694","NCT03794076","Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia","Cromoglicte Adjunctive Therapy for Outpatients With Schizophrenia","CATOS","Inclusion Criteria:\n\n* Written informed consent.\n* Both genders, ages 18-60 years\n* Schizophrenia \u002F schizoaffective disorder (DSM V).\n* Treated with the same APD for at least 60 days; Stable dose of APD for \\> 1 month, continued throughout the study.\n* PANSS total score of 60 and Score 4 or more on one or more items of the 'positive' syndrome items (P1-P7)\n* Preference for patients with duration of psychosis less than 7 years.\n\nExclusion Criteria:\n\n* No illicit substance use in last 30 days\u002Fno dependence in 6 months with the exception of methadone treatment for opioid withdrawal.\n* History or current medical \u002Fneurological illnesses that may lead to an unstable course with the exception of epilepsy which is well-controlled on an antiepileptic medication for at least 6 months.\n* Pregnancy.\n* History of immune disorders, HIV infection, or receiving immune-suppressants or immuno-modulators, e.g., steroids.\n* Current or prior treatment with CGY or History of hypersensitivity to CGY.\n* Intellectual disability as defined in DSM V.","65 Years",{"count":53,"type":21},160,[24,25],"This is a double blind adjunctive randomized controlled trial for schizophrenia using cromoglicate.",[28,29],[58,59,60],"schizophrenia","schizoaffective disorder","cromoglicate","2026-03-16",{"date":63,"type":36},"2026-03-19",{"date":65,"type":36},"2019-04-01",{"date":67,"type":21},"2028-06",{"name":42,"class":43},1,""]